Azafaros is a clinical-stage company focused on developing therapies for severe rare metabolic disorders, particularly lysosomal storage disorders
Azafaros is a clinical-stage company focused on developing therapies for severe rare metabolic disorders, particularly lysosomal storage disorders. Their lead program, nizubaglustat, is designed to treat conditions like GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.